BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological evaluation of novel triazoloquinazolinone derivatives as SHP2 protein inhibitors. 2021

Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
School of Pharmaceutical Sciences, Guizhou University, Guiyang, China.

A novel series of triazoloquinazolinone derivatives were designed, synthesised, and evaluated for their in vitro biological activities against the SHP2 protein. Moreover, some compounds were evaluated against A375 cells. The results revealed that target compounds possessed moderate to excellent inhibitory activity against SHP2 protein, whereas compounds 12f, 12l, 12j, 17e, and 17f have strong antiproliferative activity on A375 cells. The compound 12l showed remarkable cytotoxicity against A375 cells and a strong inhibitory effect against SHP2 protein when compared with SHP244. The structure-activity relationships (SARs) indicated that electron-donating groups (EDGs) on phenyl rings are beneficial for improving the antitumor activity; compounds with a hydroxyl substituent at the 2-position of phenyl ring exhibited superior activities than compounds with a substituent at the 4-position. In addition, compound 12l displayed improved physicochemical properties as well as metabolic stability compared to SHP244. Our efforts identified 12l as a promising SHP2 protein inhibitor, warranting its further investigation.

UI MeSH Term Description Entries
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole

Related Publications

Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, synthesis and biological evaluation of novel triazoloquinazolinone and imidazoquinazolinone derivatives as allosteric inhibitors of SHP2 phosphatase.
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
July 2020, Bioorganic chemistry,
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, synthesis and biological evaluation of naphthostyril derivatives as novel protein kinase FGFR1 inhibitors.
February 2015, Journal of enzyme inhibition and medicinal chemistry,
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, synthesis and biological evaluation of chromone derivatives as novel protein kinase CK2 inhibitors.
August 2022, Bioorganic & medicinal chemistry letters,
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors.
November 2022, Bioorganic chemistry,
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors.
September 2019, Molecules (Basel, Switzerland),
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
January 2021, Bioorganic & medicinal chemistry,
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors.
September 2018, European journal of medicinal chemistry,
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
March 2010, European journal of medicinal chemistry,
Rongshuang Luo, and Zhongyuan Wang, and Dali Luo, and Yumei Qin, and Chunshen Zhao, and Di Yang, and Tian Lu, and Zhixu Zhou, and Zhuyan Huang
Design, Synthesis and Biological Evaluation of Stilbene Derivatives as Novel Inhibitors of Protein Tyrosine Phosphatase 1B.
December 2016, Molecules (Basel, Switzerland),
Copied contents to your clipboard!